Editing Mifepristone (section)

===1997–1999===
On 8 April 1997, after buying the remaining 43.5% of Roussel-Uclaf stock in early 1997,<ref>{{cite news | vauthors = Moore SD, Kamm T, Fleming C |date=11 December 1996 |title=Hoechst to seek rest of Roussel-Uclaf; expected $3.04 billion offer would add to the wave of drug-sector linkups |newspaper=The Wall Street Journal |page=A3}}<br />{{cite news | vauthors = Marshall M |date=11 December 1996 |title=Hoechst offers to pay $3.6 billion for rest of Roussel|newspaper=The Wall Street Journal |page=A8}}<br />{{cite news |agency=[[Bloomberg News]] |date=11 December 1996 |title=Hoechst to buy rest of Roussel |newspaper=[[The New York Times]] |page=D4 |url=https://www.nytimes.com/1996/12/11/business/hoechst-to-buy-rest-of-roussel.html |url-access=subscription |url-status=live |archive-url=https://web.archive.org/web/20160625124549/http://www.nytimes.com/1996/12/11/business/hoechst-to-buy-rest-of-roussel.html |archive-date=25 June 2016 }}</ref> Hoechst AG ({{USD|30|1996}} billion annual revenue) announced the end of its manufacture and sale of Mifegyne ({{USD|3.44|1996}} million annual revenue) and the transfer of all rights for medical uses of mifepristone outside of the United States to [[Exelgyn]], a new single-product company immune to antiabortion boycotts, whose CEO was former Roussel-Uclaf CEO Édouard Sakiz.<ref>{{cite news|agency=[[Bloomberg News]]|date=9 April 1997|title=Pill for abortion ends production|newspaper=[[The New York Times]]|page=D2|url=https://www.nytimes.com/1997/04/09/business/pill-for-abortion-ends-production.html|url-status=live |url-access=subscription |archive-url=https://web.archive.org/web/20160625134359/http://www.nytimes.com/1997/04/09/business/pill-for-abortion-ends-production.html|archive-date=25 June 2016}}<br />{{cite news | vauthors = Jouzaitis C |date=9 April 1997 |title=Abortion pill maker bows to boycott heat; German firm gives up RU-486 patent; little impact likely in U.S. |newspaper=Chicago Tribune |page=4 |url=https://pqasb.pqarchiver.com/chicagotribune/access/11401570.html?dids=11401570:11401570&FMT=ABS&FMTS=ABS:FT |url-status=dead |archive-url=https://web.archive.org/web/20130218193350/http://pqasb.pqarchiver.com/chicagotribune/access/11401570.html?dids=11401570%3A11401570&FMT=ABS&FMTS=ABS%3AFT |archive-date=18 February 2013 }}<br />{{cite news | vauthors = Lavin D |date=9 April 1997 |title=Hoechst will stop making abortion pill |newspaper=The Wall Street Journal |page=A3}}<br />{{cite journal |date=18 April 1997 |title=Roussel-Uclaf to transfer RU 486 rights |journal=Reprod Freedom News |volume=6 |issue=7 |page=8 |pmid=12292550}}<br />{{cite journal | vauthors = Dorozynski A |date=19 April 1997 |title=Boycott threat forces French company to abandon RU486 |journal=BMJ |volume=314|issue=7088 |page=1150 |pmid=9146386 |pmc=2126515 |doi=10.1136/bmj.314.7088.1145m}}</ref> In 1997, Gideon Richter would withdraw from efforts to manufacture mifepristone in the United States following opposition from pro-life groups, which led to Danco filing a [[breach of contract]] lawsuit.<ref>{{Cite news|url=https://www.washingtonpost.com/archive/politics/1997/06/12/abortion-pills-us-sponsor-suing-hungarian-drug-firm/f08f9b4e-36ea-45d1-aa1e-3c89f5496370/|title=ABORTION PILL'S U.S. SPONSOR SUING HUNGARIAN DRUG FIRM|date=1997-06-12|work=[[The Washington Post]] |url-access=subscription |access-date=2024-06-13|language=en-US|issn=0190-8286}}</ref> In 1999, Exelgyn won approval of Mifegyne in 11 additional countries, and in 28 more countries over the following decade.<ref name="Gynuity 2009">{{cite web|date=4 November 2009|title=List of mifepristone approval|location=New York|publisher=Gynuity Health Projects|url=http://gynuity.org/downloads/mife_approval_2009_list.pdf|url-status=dead|archive-url=https://web.archive.org/web/20110726135110/http://gynuity.org/downloads/mife_approval_2009_list.pdf|archive-date=26 July 2011|access-date=4 May 2018}}<br />{{cite web|date=4 November 2009|title=Map of mifepristone approval|location=New York|publisher=Gynuity Health Projects|url=http://gynuity.org/downloads/Mife_approval_2009_map.pdf|access-date=11 June 2010|url-status=dead|archive-url=https://web.archive.org/web/20110726135136/http://gynuity.org/downloads/Mife_approval_2009_map.pdf|archive-date=26 July 2011}}</ref>